StockNews.com Upgrades CEL-SCI (NYSE:CVM) to “Hold”

CEL-SCI (NYSE:CVM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday.

CEL-SCI Trading Down 10.1 %

Shares of CVM opened at $0.63 on Tuesday. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00. CEL-SCI has a 12-month low of $0.63 and a 12-month high of $3.23. The firm has a market capitalization of $40.21 million, a PE ratio of -1.09 and a beta of 0.69. The stock’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $1.16.

CEL-SCI (NYSE:CVM) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, research analysts predict that CEL-SCI will post -0.52 earnings per share for the current year.

Hedge Funds Weigh In On CEL-SCI

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of CEL-SCI by 5.5% in the first quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock worth $4,189,000 after acquiring an additional 113,703 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of CEL-SCI by 29.9% in the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares in the last quarter. Thoroughbred Financial Services LLC increased its holdings in shares of CEL-SCI by 140.9% in the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares in the last quarter. Cutter & CO Brokerage Inc. increased its holdings in shares of CEL-SCI by 29.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after acquiring an additional 24,634 shares in the last quarter. Finally, Black Diamond Financial LLC grew its holdings in shares of CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after buying an additional 19,000 shares in the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.